MedTrace Logo

Senescence in Chronic Kidney Disease

NCT02848131 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-05-19

No results posted yet for this study

Summary

The study goal is to assess the effect of senescent cell clearance on senescence burden, physical ability or frailty, and adipose tissue-derived mesenchymal stem cell (MSC) functionality in patients with chronic kidney disease (CKD).

Conditions

Interventions

DRUG

Group 2: Dasatinib

Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days.

DRUG

Group 2: Quercetin

Quercetin - take four 250 mg capsules daily (total 1000 mg daily) for 3 consecutive days.

Sponsors & Collaborators

Principal Investigators

  • LaTonya J Hickson, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2027-04-30
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02848131 on ClinicalTrials.gov